CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 145 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 1.85 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,505 | +9.3% | 1,240,769 | +25.6% | 0.03% | +17.2% |
| Q2 2023 | $13,274 | -16.4% | 987,669 | +3.1% | 0.03% | -19.4% |
| Q1 2023 | $15,880 | -16.1% | 957,800 | -5.9% | 0.04% | -14.3% |
| Q4 2022 | $18,925 | -100.0% | 1,017,471 | -70.0% | 0.04% | -58.8% |
| Q3 2022 | $43,551,000 | +54.2% | 3,394,489 | -15.8% | 0.10% | +67.2% |
| Q2 2022 | $28,248,000 | -8.0% | 4,029,677 | +8.8% | 0.06% | +8.9% |
| Q1 2022 | $30,700,000 | +11.9% | 3,703,272 | -8.6% | 0.06% | +14.3% |
| Q4 2021 | $27,433,000 | -1.6% | 4,052,069 | -23.0% | 0.05% | -2.0% |
| Q3 2021 | $27,876,000 | +14.3% | 5,259,705 | +24.0% | 0.05% | +22.0% |
| Q2 2021 | $24,381,000 | +274.9% | 4,240,316 | +200.6% | 0.04% | +272.7% |
| Q1 2021 | $6,503,000 | +30.4% | 1,410,737 | -5.5% | 0.01% | +22.2% |
| Q4 2020 | $4,987,000 | +5.3% | 1,493,137 | -6.3% | 0.01% | -10.0% |
| Q3 2020 | $4,734,000 | +504.6% | 1,594,237 | +839.5% | 0.01% | +400.0% |
| Q2 2020 | $783,000 | – | 169,693 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 589,883 | $590,000 | 1.38% |
| Broadfin Capital, LLC | 8,200,000 | $8,610,000 | 0.96% |
| Avoro Capital Advisors LLC | 1,141,149 | $1,198,000 | 0.24% |
| CORRADO ADVISORS, LLC | 190,600 | $200,000 | 0.12% |
| Baker Brothers Advisors | 5,102,153 | $5,357,000 | 0.05% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 756,311 | $794,000 | 0.04% |
| Point72 Asset Management, L.P. | 2,272,816 | $2,386,000 | 0.02% |
| AGRAN LIBBIE | 44,000 | $46,000 | 0.01% |
| COMPTON CAPITAL MANAGEMENT INC /RI | 10,000 | $11,000 | 0.01% |
| KENNEDY CAPITAL MANAGEMENT LLC | 233,171 | $245,000 | 0.00% |